IRIS - Res&Arch Institutional Research Information System - Research & Archive

CRINO', Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.327
EU - Europa 3.095
AS - Asia 3.026
SA - Sud America 573
AF - Africa 109
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 11.132
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.233
SG - Singapore 1.437
IE - Irlanda 598
RU - Federazione Russa 476
BR - Brasile 452
CN - Cina 432
IT - Italia 411
SE - Svezia 394
VN - Vietnam 385
HK - Hong Kong 331
UA - Ucraina 274
FR - Francia 225
DE - Germania 216
FI - Finlandia 197
GB - Regno Unito 104
KR - Corea 98
IN - India 67
BD - Bangladesh 54
AR - Argentina 51
CA - Canada 47
PL - Polonia 39
ZA - Sudafrica 32
AT - Austria 30
MX - Messico 30
TR - Turchia 30
IQ - Iraq 28
CH - Svizzera 25
JP - Giappone 23
ID - Indonesia 21
NL - Olanda 19
UZ - Uzbekistan 19
PK - Pakistan 16
VE - Venezuela 15
EC - Ecuador 14
MA - Marocco 14
RO - Romania 13
CO - Colombia 12
ES - Italia 12
CL - Cile 10
PH - Filippine 10
TN - Tunisia 10
BE - Belgio 9
CZ - Repubblica Ceca 9
GR - Grecia 9
KE - Kenya 9
LB - Libano 9
SA - Arabia Saudita 9
HR - Croazia 8
PY - Paraguay 8
SN - Senegal 8
EG - Egitto 7
LT - Lituania 7
JO - Giordania 6
MY - Malesia 6
OM - Oman 6
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 4
ET - Etiopia 4
IL - Israele 4
JM - Giamaica 4
KZ - Kazakistan 4
NP - Nepal 4
PS - Palestinian Territory 4
TH - Thailandia 4
AO - Angola 3
AZ - Azerbaigian 3
BH - Bahrain 3
UY - Uruguay 3
AL - Albania 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GT - Guatemala 2
HU - Ungheria 2
IR - Iran 2
LV - Lettonia 2
ML - Mali 2
MU - Mauritius 2
NG - Nigeria 2
PA - Panama 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BW - Botswana 1
CD - Congo 1
CM - Camerun 1
DK - Danimarca 1
GE - Georgia 1
GM - Gambi 1
GP - Guadalupe 1
HN - Honduras 1
KG - Kirghizistan 1
Totale 11.117
Salva come PNG Salva come JPEG
Città #
Singapore 989
Chandler 628
Dublin 598
San Jose 382
San Mateo 345
Hong Kong 330
Boardman 225
Ashburn 221
Santa Clara 183
Dong Ket 169
Andover 146
Medford 145
Princeton 143
Jacksonville 135
Moscow 132
Perugia 132
Altamura 129
Lauterbourg 125
Lawrence 123
Beijing 116
Ann Arbor 107
Seoul 98
Wilmington 98
Munich 83
Ho Chi Minh City 70
Los Angeles 54
Hanoi 52
São Paulo 51
New York 45
Saint Petersburg 45
Helsinki 39
The Dalles 36
Norwalk 31
Piscataway 31
San Paolo di Civitate 28
Brooklyn 24
Warsaw 23
Frankfurt am Main 22
Tokyo 22
Des Moines 21
Rio de Janeiro 19
Turku 19
Chicago 18
Johannesburg 18
Nuremberg 16
Orem 16
Redwood City 16
Boston 15
Mexico City 15
Falls Church 14
London 14
Woodbridge 14
Denver 13
Dhaka 13
Montreal 13
Baghdad 12
Bucharest 12
Chennai 12
Curitiba 12
Da Nang 12
Guangzhou 12
Poplar 12
San Francisco 12
Houston 11
Lausanne 11
Tashkent 11
Toronto 11
Vienna 11
Brussels 9
Dearborn 9
Manchester 9
Phoenix 9
Shanghai 9
Stockholm 9
Atlanta 8
Dakar 8
Den Haag 8
Falkenstein 8
Istanbul 8
Nairobi 8
Osijek 8
Tianjin 8
Auburn Hills 7
Biên Hòa 7
Cape Town 7
Dallas 7
Haiphong 7
Santo André 7
Amsterdam 6
Belo Horizonte 6
Buenos Aires 6
Caracas 6
Goiânia 6
Guayaquil 6
Lahore 6
Lappeenranta 6
Mumbai 6
Paris 6
Salvador 6
Santiago 6
Totale 6.992
Salva come PNG Salva come JPEG
Nome #
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study 141
Afatinib In Egfr Mutant Non-small-cell Lung Cancer Patients With Acquired Resistance To Reversible Egfr-tkis 129
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer 126
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 125
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 124
Significato prognostico dell’espressione immunoistochimica di Insulin like growth facor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 121
P-126 * PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER 120
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease 118
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 118
A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung 116
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids 115
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer 115
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. 114
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer 110
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. 108
A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments 106
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 106
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 105
Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma 104
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 104
Acute myeloblastic leukemia after adjuvant chemo¬therapy with melphalan in breast cancer. Case report with cytogenetic analysis. 103
Phase II study of weekly paclitaxel and trastuzumab in anthracycline and taxane pretreated patients with HER2 overexpressing metatastatic breast cancer 103
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment 103
Non-coding RNAs in lung cancer 103
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors 101
An approach for optimally extending mathematical models of signaling networks using omics data 101
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 100
A prospective study on survival in cancer patients with and without venous thromboembolism. 97
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 96
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 96
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 94
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort 94
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients 94
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 94
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free servival in resected non-small-cell lung cancer patients. 93
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. 93
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients Results of the First Italian External Quality Assurance Scheme 93
Carcinomi mammari "triple negative": studio dei fattori prognostici e predittivi. 92
Espressione dei recettori HER nei carcinomi non a piccole cellule del polmone 92
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology 92
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 92
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. 91
Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). 90
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 90
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 90
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 90
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? 89
PD-L1 quantification across tumor types using the reverse phase protein microarray: Implications for precision medicine 88
High coexpression of both insulin-like growth factor receptor 1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients 87
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment 87
MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non-small Cell Lung Cancer 87
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 87
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 86
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 86
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 85
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390) 85
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. 83
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. 83
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 83
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology (vol 30, pg 142, 2012) 82
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 82
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 82
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 82
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 80
Carcinomi mammari “triple negative”: studio dei fattori prognostici e predittivi 79
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 79
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology 78
Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. 77
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. 77
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study 76
Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer. 76
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 76
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 75
Carcinomi mammari “tripli negativi”: significato biologico e prognostico dell’espressione di ERCC1. 75
Microinvasive breast cancer: clinical pathological characteristics and treatment. Experience from two institutions 75
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer 75
ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 74
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients 74
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 74
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 74
Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors 73
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 73
Significato prognostico dell'espressione immunoistochimica di insulin like growth factor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 71
Antigen-Presenting Signaling Events in the Tumor Ecology Associate with Response to Anti-PD-1 Treatment in Lung Cancer 70
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 70
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study 70
Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop 70
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 70
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer 68
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases 68
Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial 67
Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT) 66
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) 66
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 65
Emerging drugs for small cell lung cancer - an update 65
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. 64
INSULIN-LIKE GROWTH FACTOR RECEPTOR 1 (IGF1R) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION AND EXPRESSION IN SURGICALLY RESECTED NSCLC 63
Impact of Kras Codon Sub-types In A Phase Ii Second-line Trial In Kras-mutant Advanced Non-small Cell Lung Cancer (nsclc) of Selumetinib Plus Docetaxel Versus Docetaxel Alone 62
ERCC1 and RRM1 mRNA expression in resected patients with non-small-cell-lung-cancer (NSCLC). (A study of the Perugia multidisciplinary team for thoracic tumors) 61
Totale 8.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.265
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.265
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021296 0 0 0 0 0 0 0 0 0 41 64 191
2021/20221.152 29 237 12 75 19 11 7 446 14 12 119 171
2022/20232.061 149 394 16 180 157 206 0 96 772 1 69 21
2023/2024630 44 75 51 16 6 1 122 7 47 29 112 120
2024/20251.735 43 168 100 47 270 48 32 122 351 114 236 204
2025/20263.860 296 316 227 551 511 352 719 236 396 256 0 0
Totale 11.418